This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk14: Good morning, and welcome to Orthopediatrics Corporation's first quarter 2024 earnings conference call. At this time, all participants are in a listen-only mode. We will be facilitating a question and answer session towards the end of today's call. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Tripp Taylor from Gilmartin Group for a few introductory comments.
spk19: Thank you for joining today's call. With me from the company are David Bailey, President and Chief Executive Officer, and Fred Height, Chief Operating and Financial Officer. Before we begin today, let me remind you that the company's remarks include forward-looking statements within the meaning of federal securities laws, including the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to numerous risks and uncertainties, and the company's actual results may differ materially. For a discussion of risk factors, I encourage you to review the company's most recent annual report on Form 10-K, which was filed with the SEC on March 8, 2024. During the call today, management will also discuss certain non-GAAP financial measures, which are supplemental measures of performance. The company believes these measures provide useful information for investors evaluating its operations period over period. For each non-GAAP financial measure referenced on this call, the company has included a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures in its earnings release. Please note that the non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for orthopediatrics financial results prepared in accordance with GAAP. In addition, the content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, today, May 7th, 2024. Except as required by law, the company undertakes no obligation to revise or update any statements to reflect events or circumstances taking place after the date of this call. With that, I'd like to turn the call over to David Bailey, President and Chief Executive Officer.
spk07: Thanks, Trent. Good morning, everyone, and thank you for joining us on our first quarter 2024 conference call. As we start all earnings calls, I'd like to begin by highlighting that we helped a record 27,600 kids in the first quarter of 2024. This remarkable 47% year over year growth is the metric we're most proud of out of all of the stuff we'll share with you today. It embodies our fundamental commitment to helping children and demonstrates our ability to continue to expand our reach and create a more significant impact for children worldwide. So today, we're excited to join you live from just outside of Washington, D.C. at the ePOSNA conference, where POSNA and ePOS are collaborating to host a joint annual meeting. This is the largest pediatric orthopedic conference in the world. And once again, Orthopediatrics is the leading sponsor of this event. The shared mission across our three organizations will be advanced through clinical data presentations, and educational sessions highlighting the most cutting-edge pediatric orthopedic treatments and technologies. We're looking forward to connecting with our customers and colleagues this week, and there is no better place to deliver our exciting business update. Orthopediatrics is off to a great start in 2024, generating first quarter revenue of $44.7 million, representing growth of 41% compared to the first quarter of 2023. Driven by strong performance across the businesses, we continue to demonstrate robust top-line growth, maintain healthy margins, and outperform our adjusted EBITDA expectations. The execution of our business plan is delivering both financial results and progress on our strategic initiatives. Looking closer at the quarter, after an initial RSD spike seen in early January, revenue and surgery scheduling quickly bounced back. Children's hospitals have learned to manage RSV waves efficiently and effectively mitigate disruptions previously seen. Overall, improvements in the surgical environment are tracking our expectations. Hospitals are now better staffed, and the training of new associates is contributing to improved efficiency. Improvements continue every month, and by our estimations, we're approximately 95% back to normal levels. Given the seasonality of our business, The improved children's hospital's capacity will be tested in these critical summer months. Throughout the next few quarters, we will continue to monitor this progress closely. However, our confidence continues to increase that this headwind will have less and less of an impact moving forward toward a completely normalized state. We've built a business with a highly diversified portfolio that surrounds our surging customers with high-technology products that continue to take market share and drive orthopediatrics growth. During the quarter, the global trauma and deformity, international scoliosis, and our newly formed and rapidly expanding specialty bracing business, or OPSB, were all particularly strong. First quarter, global TND was very strong, with 42% year-over-year growth led by sales of Pega products, PNP Femur, Orthex, early sales of PNP Tibia, and growth within the OPSB franchise as well as the addition of Boston O&P's T&D product sales. P&P Tivia demand continues exceeding expectations, and DF2 revenue has started strong. In addition, total surgeon users of X6 increased by 29% in the first quarter, and total accounts increased by 37%. We believe these numbers imply strong quarters are ahead of us. Looking at our international business, We reported strong overall growth of 33%, led by a rebound in scoliosis and very strong sales of TND, with X6 at 59% growth and PEGA at 152% growth. Operations commenced at our recently established German headquarters, which is improving customer service and increasing surgeon access to orthopediatrics products across the country. We are already seeing a return on this investment, as the German business grew 22%. We're also seeing very high growth in Canada, where recent product registration and our account conversion strategy have been extremely effective, leading to large share gains in some of the country's largest, most prestigious children's hospitals and global teaching institutions. In addition, the macro environment in Brazil is improving. This momentum internationally is expected to continue throughout 2024. Scoliosis revenue had substantial impact 44% growth, led by domestic apathics, international sales in Europe and Latin and South America, along with another quarter of share-taking in our Fusion franchise, as well as the addition of Boston O&P Scoliosis custom bracing product sales. We expected the OUS Scoliosis to rebound aggressively in 2024 and to act as a tailwind, and this is exactly the trend we're seeing to start the year. OPSB contributed to growth in both the T&D and scoliosis businesses as a result of Boston O&P acquisition, coupled with increased sales from products unrelated to Boston O&P clinics, such as MDO, DF2, Ora Medical, and Rhino. Increases in OPSB sales continue to rise as we hire additional sales staff exclusively focused on this franchise, and we are confident that as we build this business, there is a massive opportunity to capture growth. The various levers driving the next phase of orthopediatrics growth and profitability are becoming more visible, and we remain quite bullish about our prospects for 2024 and beyond. For the remainder of the year, we're focused on continuing legacy product growth, launching several key new organic products, expanding Pegasales, capitalizing on normalization in international markets, publishing positive longer-term Appifix data, an execution on OPSB, and an early start in digital healthcare. The continued advancement of our strategic initiatives paired with our strong financial position will enable us to execute our long-term goals. With a solid start for the year, we are raising our revenue guidance for full year 2024 to $200 to $203 million, representing growth of 34 to 36%. The plethora of growth drivers outlined have positioned this business to continue growing on the top line while improving profitability on our way to cash flow break even sooner. Moving to our revenue segments. In the first quarter of 2024, we generated total trauma and deformity revenue of $33.3 million, representing growth of 42% compared to the prior year period. This quarter saw strong performances from PEGA products, trauma, specifically P&P Tibia, X6, and OPSB, as well as the addition of Boston O&P T&D product sales. Our prior investments in set allocations are generating a return and driving meaningful share gains for the T&D business across the entire breadth of products, specifically Pega, which once again grew nearly 50% globally. Sales of Pega continue to be better than we ever expected. As we more deeply penetrate our U.S. accounts, with the full PEGA product portfolio, and we ramp international sales. Now that the distributor and agency transition is complete OUS, Pega will likely to continue this trajectory globally in 2024 and for the foreseeable future. Excitedly, the full US market release of PMP Tibia and Gyro are underway, with several sets expected to arrive at accounts in the second quarter and every quarter thereafter for the next several quarters. The full market release of DF2 is also underway, and there is extremely high demand for this product, and it's helping grow OPSB sales. These products are great additions to our portfolio and will create an immediate impact. Product portfolio expansion remains a top priority for the business. We seek to surround our surgeon customers with everything they need to treat each patient and treat more children. Orthopediatrics is building a dominant share position across our entire T&D portfolio. Each quarter, more customers are using more of our products, driving increased market share. Adding new high technology products like Pega helps advance the key account conversion strategy. The T&D business is increasingly well positioned to continue to deliver sustainable growth for the next several years. On the R&D side, there are several exciting products within the surgical side of our T&D business. We're making great progress developing our entirely new Pediatric Plating Platform, or P3, which we expect will be world-class and spawn further share-taking opportunities for us within our plating franchise. We've also made solid strides on new external fixation devices that will continue the growth trajectory of our X6 franchise. Further, there will be several new CE Mark products that are positioned to launch in the EU market in the coming year to 15 months. The orthopediatrics non-surgical specialty bracing business, or OPSB, is performing extremely well, and we continue to view this franchise as a significant opportunity to help more kids. Before diving into some of that progress, I want to reiterate the OPSB opportunity briefly. In addition to furthering our strategy to provide pediatric orthopedic surgeons with everything they need to treat children, we see this as another opportunity for market dominance as we scale a historically fragmented market to become the clear-cut leader. 80% of pediatric orthopedic care is delivered outside of the operating room, and we estimate the U.S. non-surgical specialty bracing market is at minimum $775 million in total and conservatively a $500 million opportunity within the top 300 children's hospitals. From a business model's perspective, importantly, these custom-fit devices do not require the upfront capital investment in consigned inventory or instrument sets. As mentioned on our previous calls, we continue to successfully execute a build aggressively strategy in OPSB and anticipate it to grow very rapidly in the coming several years. OPSB is in the early innings of what we believe can be a business well in excess of $100 million in the coming years. The planned Salesforce expansion, product developments, and the addition of new clinics will scale this business rapidly. Progress expanding the sales force and integrating our specialty bracing products with Boston's are already contributing to growth. Our existing R&D pipeline will support launching four to five new products within the OPSB business every year. Lastly, we've identified several new clinic opportunities and expect these to have a major impact as early as next year. Moving on to the scoliosis business. In the first quarter of 2024, we generated revenue of $10.2 million, representing global growth of 44% compared to the prior year. This global growth was led by a return in international sales in Latin and South America, new business in Europe, and strong Appifix growth, as well as the addition of Boston O&P Scoliosis custom bracing product sales. First quarter domestic sales increased by 38%, led by the addition of Boston Brace from the Boston O&P product portfolio. We are proud to add the most studied and utilized scoliosis brace in the world, and a product that is considered to be the premier system for non-operative treatment of scoliosis and kyphosis to the OPSB portfolio. We're pleased with the rebound from the international scoliosis business, which outpaced our domestic business, generating 114% growth. We expect to see a continuation of strong international growth, coupled with a robust summer surgery schedule in the coming quarters. The increased number of total response users over 2023, earnouts on 70 units placed in 2023, continued apathics growth, improvements in South America, and our European launch all together keep us bullish on 2024 scoliosis growth. The scoliosis R&D pipeline is continuously progressing, and the funnel is rich with highly novel technologies that solve major unmet needs for our customers, specifically for patients with early-onset scoliosis, a category in which we have never had products before. In the first quarter, we launched the first of three products in the EOS space. The first surgeries with response rib and pelvic were completed in the first quarter, producing excellent results. we've made great progress with our new growing spine system for EOS called VertiGlide and hope to have FDA approval secured in the second half of 2024. Further, the FDA recently classified our electromechanical growing spine rod, ELE, with the breakthrough device designation, both a major milestone on our way to FDA approval and a strong endorsement of ELE's potential for patients suffering from EOS. Lastly, Substantial progress has been made on the development of our next generation fusion system. The next 18 to 24 months will be the most prolific period of new product development and launches in OP scoliosis history, transforming the already impressive product portfolio into the most substantial offering available to surgeons treating pediatric scoliosis. Moving on to international. Overall, international growth improved substantially compared to the prior quarter, generating revenue of $10.4 million, delivering 33% year-over-year growth. This major rebound was supported by a return to normal ordering patterns for Scoliosis products in South America, the launch of Scoliosis in Europe, Pega products, and general demand across the entire T&D portfolio. The international growth seen this quarter is very encouraging. As I mentioned earlier, we are seeing meaningful traction within several of our core international markets. The results we've seen in Germany are particularly pleasing as we begin to reap the benefits of our investment in building a direct sales channel and local customer service. As we await the notified body audit to finalize our EU MDR status, we are thrilled about all the progress we've made internationally and that 2024 has started off on such a strong footing. We expect completion of our audit in the second half of 2024, enabling the potential launch of several new products in Europe shortly thereafter. Given the general lack of new pediatric orthopedic product launches in Europe over the past four to five years, it is particularly impressive that we've made so much headway and have many more opportunities in front of us. Overall, the international business is set up nicely. We believe that the first quarter represents a great start to an improved 2024. That brings us to surgeon training and education. Since inception, facilitating educational opportunities for the pediatric orthopedic community has been a foundational component of orthopediatric strategy. That's why we are live from the EPOSNA today, and we look forward to updating you on how productive and impactful this meeting will be for the pediatric orthopedic community. Back in April, the company was again a lead sponsor of ICSS, a meeting that offers a comprehensive program of lectures given by an outstanding international faculty and didactic cadaver labs focused on the cervical spine, lumbosacral junction, neuromonitoring, and various aspects of scoliosis. This interactive forum was a great opportunity for us to engage with pediatric orthopedic fellows and attending surgeons and provide training on the latest technologies and surgical techniques. We highlighted response and the new pelvic fixation system at this year's meeting. In the quarter, we conducted a total of 46 unique learning experiences, highlighting over 162 different product touches, including labs, workshops, and sawbone stations, and we reached over 1,100 healthcare providers and other staff members. As we continue advancing our ongoing commitment to training the next generation of pediatric orthopedic surgeons and leading innovation, in our subspecialty around the world. Lastly, because of the continued focus on our people and culture building, I want to again highlight that for the eighth time, Orthopediatrics was named as one of the best places to work in Indiana. We are committed to fostering a culture that is positive, engaging, and allows our associates to do their best work. This has become a key aspect of our competitive advantage and continues to expand our ability to help more kids around the world. With that, I'll turn the call over to Fred to provide more detail on our financial results. Fred?
spk05: Thanks, Dave. Our first quarter 2024 worldwide revenue of $44.7 million increased 41% compared to the first quarter of 2023. Growth in the quarter was driven primarily by strong performance across global trauma and deformity, international scoliosis, and OPSB as well as the addition of Boston O&P. U.S. revenue was $34.3 million, a 44% increase from the first quarter of 2023. Growth in the quarter was primarily driven by our trauma and deformity product lines, scoliosis, and OPSB as well as the addition of Boston O&P sales. We generated total international revenue of $10.4 million, representing growth of 33% compared to the first quarter of 2023. Growth in the quarter was primarily driven by trauma and deformity, scoliosis, and OPSV. In the first quarter of 2024, trauma and deformity global revenue of $33.3 million increased 42% compared to the prior year period. Growth was primarily driven by strong growth across numerous product lines, specifically arcane-related screws, PMP femur, PD plates, external fixation, and the PEGA systems, as well as the addition of Boston O&P trauma and deformity correction product sales. In the first quarter of 2024, scoliosis revenue of $10.2 million increased 44% compared to the prior year period. Growth was primarily driven by increased sales of our Response 5560, ApiFix systems, and revenue generated from 7D technologies, as well as the addition of Boston O&P Scoliosis custom bracing product sales. Finally, sports medicine other revenue in the first quarter of 2024 was $1.2 million, compared to $1.1 million in the previous year period. Turning to set deployment, $4.3 million of sets were consigned in the first quarter of 2024, compared to $3.0 million in the first quarter of 2023. The increase was driven by the strategic decision to bring in inventory earlier in the year and deploy a greater percentage of the annual sets prior to our busy summer months. Touching briefly on a few key metrics. For the first quarter of 2024, gross profit margin was 72% compared to 75% for the first quarter of 2023. The decrease in gross profit margin was driven primarily by increased international set sales in the first quarter of 2024, as well as less purchase price variance released in the first quarter of 2024 compared to 2023. Total operating expenses increased $9.7 million, or 30%, to $41.9 million in the first quarter of 2024. The increase was mainly driven by incremental personnel costs associated with increased headcount, increased commissions, and the addition of the Boston O&P acquisition. Sales and marketing expenses increased $1.6 million, or 13%, to $14.2 million in the first quarter of 2024. The increase was primarily driven by increased sales commission expense, with a limited increase coming from the addition of Boston O&P acquisition. General and administrative expenses increased $7.6 million, or 44%, to $24.7 million in the first quarter of 2024. The increase was driven primarily by the addition of Boston O&P acquisition, as well as resources to support the continued expansion of our business, and increases in non-cash expenses such as stock compensation, depreciation, and amortization. Research and development expenses increased $0.6 million, or 23%, to $3.0 million in the first quarter of 2024, due to the incremental product development and the addition of personnel to support the future growth of the business, as well as the addition of the Boston O&P acquisition. Total other expense was $0.6 million for the first quarter of 2024, compared to $1.2 million of other income for the same period last year. In the first quarter of 2023, we recognized a $0.6 million favorable adjustment to contingent consideration that did not repeat in the first quarter of 2024, as well as increased interest expense from our $10 million mid-cap loan. Adjusted EBITDA loss was $1.1 million in the first quarter of 2024, and this compares to a loss of $2.1 million in the first quarter of 2023. We ended the first quarter with $49.7 million in cash, short-term investments, and restricted cash. Cash usage in the first quarter of 2024 includes $22 million paid for Boston O&P, increased set deployment, as well as increased inventory to support future set deployments. With our current cash position, as well as our debt facility, we are well capitalized to continue to execute on our long-term strategy. Given our strong balance sheet, positive annual adjusted EBITDA, our line of sight to cash flow breakeven, and the addition of Boston O&P, we are in a position of tremendous strength. Turning to guidance, we are raising our expectation for full-year 2024 revenue from the previously announced $197 to $200 million up to $200 to $203 million, representing year-over-year growth of 34% to 36%. We continue to expect to generate between $8.0 to $9.0 million of adjusted EBITDA in 2024. Additionally, we continue to expect less than $20 million of new sets deployed in 2024. This represents our continued focus on driving the business to cash flow breakeven sooner rather than later. As mentioned, this year, we plan to deploy sets earlier in the year compared to prior years. I will now turn the call back over to Dave for closing remarks.
spk07: Thanks, Fred. Looking at the first quarter, we are extremely proud of how we've started 2024 and are confident that we will continue this momentum into the remainder of the year and beyond. We continue to capture share across the entire business, record robust top-line growth, maintain healthy margins, and outperform our EBITDA expectations. We will continue to move toward profitability growth and cash flow breakeven as we execute our strategic initiatives to drive value and capitalize on our opportunities. 2024 will be a tremendous year for orthopediatrics, and I look forward to updating you again soon. In closing, I'd like to thank our surgeon partners, my OP associates, our investors, and all of the innovators in pediatric health care for standing together to help kids. Operator, let's open the call for Q&A.
spk14: Thank you. As a reminder, to ask a question, please press star 11 on your telephone and wait for your name to be announced. To withdraw your question, please press star 11 again. Please stand by while we compile the Q&A roster. Our first question is from the line of Ryan Zimmerman with BTIG. Your line is now open.
spk18: Good morning, and congrats on a strong start to the year here. I want to ask about guidance. Two-part question here. You beat by about $3.5 million. You're raising by $3 at the midpoint. Just curious if you're seeing anything kind of ahead that you want to you're a little cautious about or maybe reserving that incremental half million. And the second part is, you know, you are passing through that 3 million adjusted EBITDA guidance to stay in the same. So just talk to us about kind of that flow through on higher revenue into the business and kind of what you're putting that to work on.
spk05: Yeah. So first of all, we're obviously very excited about 41% growth in the first quarter. It's a great start to the year and sets us up very nicely. We had some RSV in late December, a little bit of it in January, and then I think some of that December got pushed into January, which helped pretty strong January to start the quarter, which is great to see. The wild card for us, as you know, Ryan, is always the summer months, right? June and July are typically the dramatically larger months for us throughout the year, and how those summer months surgery seasons play out is really unknown until we get there. And so I think that's probably where the half a million dollars maybe is on the revenue as far as why it didn't flow through for the full year. And it's really the only thing that gives us pause, if you will, on increasing it further at this point. Okay.
spk18: And the EBITDA guide relative to the BEAT, are you putting that back in the business for us?
spk05: Yeah, the EBITDA number, the range is pretty wide. And again, the summer months are so large, that's when so much of it drops through. And so as you saw in the first quarter, it was negative 1.1, basically on or maybe a little better than our expectation. But we want to wait and see what the summer months look like, and then we can increase that as we move throughout the year.
spk18: Got it. And then just last one for me, you know, Boston O&P looks like it's been, you know, a real good contribution and asset to bring in. Dave, love to hear your thoughts on clinic development. It's really the longer-term plans of what you can do with Boston OMB relative to your broader surgical customer base.
spk07: Yeah, good question. We see, I think you've heard me say this before, Ryan, the volume of inbound interest we've gotten from our customers related to that boston omp acquisition is probably as great if not greater than any other transaction or product we've done up into this point so there's clearly a serious need out there to have you know a company focused that focused exclusively in this bracing space and providing that service that that boston has done so well in about 15 institutions in in the northeast and we want to obviously expand that to everywhere in the united states so Huge opportunity to do that. It's going to take us some time. I think by the fall this year, we'll probably be able to give some guidance as to what we think the pace is going to look like in terms of clinic expansion. But there is no shortage of opportunities for us from a clinic expansion standpoint. We have kind of an outpouring of ask here from a number of locations. And it's just going to take us some time to spin some of those things up. It's possible that we'll have some of these deals done and some clinics moving here by year end, but we're not forecasting that. We do have the opening of our first clinic inside Children's National or Nationwide Children's in Columbus, which is, I believe, the highest volume children's hospital in the United States. So that should start here in the next few months. So really positive in terms of the long term. I think what we were really most pleased to see here is the fact that As we've added the sales channel and then we've added a number of products to the MDO portfolio since the acquisition a few years ago, it's great to see all of those products already in contributing to revenue growth. Not the clinic side of this stuff, but we've talked about a three-part strategy. Number one of sales channel and selling the products we have. Number two, accelerating R&D, which we're definitely doing on pace to have four or five new products a year. And then lastly, clinic expansion and to see the first two of those portions of our strategy already start to contribute and then to think that, you know, we have this huge TAM expansion opportunity, really large growth opportunity that should really kick in in 2025 when we start to realize the benefit of clinic expansion. It's just really exciting. I think it's given us a reason to be very bullish.
spk18: Sounds good. Thanks for taking the questions, guys.
spk07: Thanks, Ryan.
spk14: Thank you. Our next question comes from the line of Matthew O'Brien with Piper Sandler. Your line is now open.
spk05: Morning. Thanks for taking the question. Just maybe to start with, oh, morning. On the Boston O&P contribution, you know, I know I think you guys had mentioned it being about a $25 million business roughly historically, and I think that's kind of what we were modeling this year. Is the increase that we're expecting in the guidance for the year, just all Boston O&P related, the extra $3 million really related to that. So it's more like $28 million. So you're kind of running ahead of schedule. Or how do we kind of frame up how well Boston O&P has done so far on its own? No, I wouldn't assume that at all. I think you can assume that it's similar to historical levels. I think as we've mentioned in the past, about 23% of that $25 million typically falls in the first quarter. 25% in the second and third quarter and 28% in the fourth quarter. But the extra $3 million is not from Boston and very pleased with the legacy business, if you will.
spk07: Yeah, Matt. I mean, we see growth across every segment at this stage. I mean, it's just really good to see really positive momentum. I do want to specify that we are seeing, you know, above average growth in OPSB, but we've been doing that for a long time, right? I mean, we have taken, ever since we took on the MDO product portfolio on the Clubfoot side and then added products last year, that business has been growing in excess of 20% really since the acquisition. And we're seeing more of that. And so the OPSB, let's say minus the Boston clinics is performing extremely well. And it's certainly adding all those product lines to the T&D growth. So yeah, from that perspective, let's say the non-Boston component of OPSB, really pleased for what we're seeing there. But listen, this is a growth story that's going across every product line right now. Okay.
spk05: Okay. That's great to hear and super encouraging. Just maybe back to that other point, I'm assuming it's too early to be getting any kind of halo effect from Boston O&P, but the peg in numbers and Some commentary about APISX and other areas seem like they're kind of, you know, the momentum there is extremely strong. So I'm just curious about just the core business or the more organic historical business, where some of that growth is coming from and the durability of some of that growth, especially PEG. I mean, I know you're not going to grow 150% every quarter with that thing, but, you know, just some of the durability that you're talking about now in the more, you know, traditional orthopediatrics franchises would be helpful. Thanks.
spk07: Yeah, I think what we're seeing, you know, first on the implant side of trauma limb deformity, I mean, it's no secret that we've put out a lot of inventory over the course of the last few years. It's also no secret that some of that inventory utilization has been maybe stifled a little bit just because of pure throughput inside children's hospitals. And so I think what we're seeing is a combination of the fact that we've landed a lot of inventory and we're starting to see a normalization almost back to normal in terms of the surgical market. And so we're seeing efficiencies in that inventory and you might assume that we're being pretty aggressive in terms of wanting to pull up some of that product launch into the first half of this year because we're starting to drive real efficiencies and see real growth from the inventory that we put out in 2022 and especially 2023. So it's good to see a lot of that legacy growth come because obviously we were betting on that when we put out that volume of inventory. I would argue that We're obviously seeing really the first returns of a lot of inventory of Pega. And so still seeing great growth domestically. I think it was about 50% globally. So stronger international, much smaller business for us. But now that we have Pega in all of our agencies and converted to all our distributors, I mean, we do expect to see pretty strong growth from Pega outside of the United States for a long time. I would also say PMP Tibia is performing better than we had expected previously. Admittedly, I think we're almost to our annual sales growth number forecast on PMP Tibia now through April. And so that's a pretty strong indicator that that product is going to work for us. And I think it is also driving a bit of a rebirth in the usage profile of PMP femur, which is our largest trauma product. So those things really cranking. And then, I mean, the numbers don't lie in terms of our ortho or the orth X growth. You know, the X6 portfolio has grown ever since we made that acquisition now, what, three and a half years ago. And to see three and a half years later, that business growing at that rate. And it's still really now just starting to catch its stride outside of the United States. You know, we think we're a top two player in children's hospitals, at least in the U.S. and the X6 market. And so, man, all of those things are working for us. And that's a good momentum as we think about heading into the balance of the year. Last thing, Apifix is, I think we're starting to benefit from some better data. We're going to have longer term and better data going forward. But Apifix is cranking and, you know, the halo was Apifix 70 drive and response sales. And that's what we've been saying for a long time. And I think the beat continues there. And as surgeons see us making investments in OPSB, surgeons see us doing the deal with Boston. I think it gives people a sense of permanence for our company. They can trust that we're going to be around a long time. It also gives people a sense of, wow, these guys are putting their money where their mouth is, that they're very serious about continuing to advance the entire field of pediatric orthopedics. And of course, that creates a big halo across the whole business, not just a few products.
spk13: Got it. Thanks so much.
spk14: Thank you. Our next question comes from the line of Rick Wise with Stiefel. Your line is now open.
spk09: Good morning, gentlemen. A couple things from me. Very exciting quarter, obviously. But getting into the weeds a little bit, Fred, maybe you can help us talk us through how to think about gross margin progress for the year, sort of from a quarterly perspective. I heard what you said about some of the gross margin, if you will, mixed pressures in the quarter that took it a little lower than we were thinking. The OUS set sales and the purchase price variances, et cetera. Can you help us understand how that plays out over the course of the year? Does it step up sequentially? Are we understanding in the second quarter, does it step up sequentially in some kind of way that sort of gets it back more to the 74%, 5% range? Just help us by quarter and the implications for the year now.
spk05: Yeah, absolutely. So the gross margin rate really varies a lot based on volume. And so over the last many, many years, the third quarter is typically the highest gross margin rate. I think it was like 77% last year. The second quarter is typically the second highest quarter. And then with the first and the fourth quarter revenues being much smaller, obviously, than those two quarters in the middle, the margin is typically a little lower in those quarters. So, yeah, I would expect an increase second quarter compared to first quarter, and then possibly another increase third quarter compared to second quarter.
spk09: So still getting to that mid-70s. kind of area for the year despite the start, or no?
spk05: Yeah. Yeah, you're still comfortable with that. Good. I think I mentioned 475 on the call last time.
spk09: Great. Turning to the pipeline, obviously, Dave, you're talking about a really exciting pipeline. I can tell you're excited about it. Maybe talk to us about a couple of things some of the organic product launches in a little more detail, which ones you'd have us focus on most and just a little more sense of timing. You highlighted a couple of them, but maybe dig into a little more. And as part of that, why this electromechanical growing rod opportunity is such a big deal and what the breakthrough designation might mean for launch expectations. A lot in there, but if you could just break some of that down.
spk07: Great. Yeah, sure. So I think the near-term opportunity, right, is with products that we just had launched here or kind of kicked off in Q3 and Q4. So PMP Tibia, as I mentioned earlier, really doing well. I mean, we have, I don't know, Fred, 15% of the sets that we'll have out on PMP Tibia. I mean, maybe 10%. So to see it performing the way it's performing with a volume of inventory that hasn't even been launched, I think that's going to be a story for us. Gyro, certainly a story for us. DF2 on the OPSB side, that was a product that we developed for fracture care for patients really under the age of four that has been well-received. So those products, kind of the here and now, we've got them in our hands. They're going well. Started doing first cases with, as I said, our first EOS product line. And you hear us talking a lot about the EOS space. That represents about 15% of scoliosis procedures. And up until this point, we've never had a product in that space. So, you know, three different products, the first of which we talked about the response ribbon pelvic that just launched, and we have sales going on and procedures going on with that. Then this verticalized device. which is another very substantial, I think will be a strong revenue producer for us. Hopefully we can get it out in the second half of this year. And then Ellie, as you mentioned, which is the device that was this electromechanical growing rod, just received breakthrough device designation. I mean, our strategy in the early onset scoliosis space is not to provide the customer with a single solution. Most of the kind of adult ortho or adult spine companies may have a single product line for early onset scoliosis. Again, true to a form, we want to surround the surgeon with everything they could use across that very, very complicated set of indication. And so very excited. I think all of that creates, again, a seriousness in our product portfolio that requires the top institutions in the world to very seriously because we would be the only company in the world with that type of portfolio for that really difficult set of circumstances. The FDA, the breakthrough device designation essentially allows us to have a direct one-on-one with FDA to process the approval of this device. Certainly, there's no guarantee, Rick, that it gets approved, but based on our testing and based on, you know, the capacity to have these one-on-one discussions with FDA, and get a very clear sense of what FDA wants to see from us to get this device approved, it gives us a lot of confidence that we're going to be able to do that. And I think, you know, it's the first time in our company's history, and maybe that's why I'm personally so excited about this. It's the first time in our company's history where we've ever had a technology that was deemed so significant to the healthcare of pediatric patients that it got treated this way by the FDA. And so I think, you know, I can't imagine a stronger indication of the need profile for a device like this. And for those of us who have been around a while, there's a certain, well, it's just a realization of some of our dreams to be able to get involved in some, not just shaping kids' lives or helping kids improve life, but in some of these procedures, these are potentially life-saving surgeries. And that's, again, I just think it's a real accomplishment for the company. And we think within the next year or so, that device can be out and be implanted in children. And that's a real breakthrough for us.
spk08: That's exciting. Thanks for all the color. Thanks, Rick.
spk14: Thank you. Our next question comes from the line of Mike Madsen with Needham & Company. Your line is now open.
spk02: Yeah, thanks. So I wanted to ask about Europe. I think there was some commentary that you're expecting some new product clearances there, and you mentioned an audit or something. Can you just provide a little more detail on what's happening there? It sounds like it could be meaningful in terms of the number of new products you're expecting.
spk07: Yeah, great question, Mike. So basically, you can think about our product portfolio and how it's developed over the course of the last four years. and assume that almost none of those products that we've developed, particularly organically, none of those products have hit the European market yet. And so, you know, if you just look at the slide deck and see how much we have developed and put out into the US market and certain other markets outside of the US, most of that hasn't hit Europe, yet we're still growing very rapidly in the European market. So you can kind of think of this as really a massive opportunity for us to launch, you know, several new brands that are new to europe you know here we're at the european the combination meeting between the epos the european pediatric orthopedic society and the pediatric society of north america here in dc i mean a lot of these surgeons have seen these products they'll certainly see them exhibited here but they haven't had access to those products in markets like germany uk ireland uh italy france spain um and so this is a big deal for us when we can get this approved We are ready for the EUMD audit, EUMDR audit. Our technical files, everything is updated. We're ready to roll. It's just a question, frankly, of getting notified body into our offices. They're backed up with all kinds of these audits. And so as soon as we get that audit done and we will be ready to start launching these products, I'm not certain we can put a date. Is it November or December or early next year? That's why we've kind of said 12 to 15 months. But when it happens, It's a big deal for us, and I think it represents the launch of almost four or five years of U.S. products into the European market.
spk02: Okay, thanks. And then I know that you don't really disclose your sort of organic growth, but if we assume that Boston O&P was sort of like five and a half million, it implies about 24% growth for the non-OMP business. So You know, it seems like it's safe to assume your organic growth was probably over 20%.
spk07: I mean, is that reasonable? I'd say that's an extremely reasonable assessment, Mike. Yeah.
spk02: Okay.
spk07: All right. Thank you.
spk14: Thank you. Our next question comes from the line of Dave Turkley with Citizens JMP. Your line is now open.
spk17: Hey, good morning, guys. Sorry, I've been bouncing around a little, so I hope I asked something that hasn't been asked, but... You mentioned, I think, that you're going to hire some staff for Boston. And I was just curious, could you just refresh our memory in terms of the footprint that you have today? And then I think you even said that you think that you could build that to $100 million. What kind of headcount came with them? And how many people do you need to add? And how quickly can you do that?
spk07: Yeah. Yeah. So what we've been talking about, Dave, is just the scaling of the sales force. So when we came, when we acquired Boston and MD Orthopedics, you know, literally there was no direct sales staff. We had a couple of people that were kind of sales managers and we have some really great folks that have been helpful, you know, kind of one person teams really leading in the United States. And then a few people outside of the United States that have done great for Boston and for particularly MDO. and you know now we're trying to get those people and others some uh some an actual sales force and so the aspiration here in 2024 was to have about 20 people added within the sales channel and we want to partner those people with our current u.s and international distributors we don't want these people to be entirely separate so they show up on the doorstep of a customer who they don't know obviously we have very close relationships with really every pediatric orthopedic surgeon around the world and so we want to be able to leverage You know, our relationship and the fact that they know orthopediatrics and then bring some people into the sales channel that focused exclusively on the non-operative side. You know, that aren't obligated to stand in the operating room and work with surgeons all day long, but certainly can work in their clinics. And so that's what we're really talking about. We have added, I would say, I don't know for sure, but I think we probably added the majority of those salespeople already. And so those costs have started to figure into our P&L already. And, you know, obviously we've got that forecasted for the balance of the year. And, you know, as that portfolio expands and clinics expand, and maybe even our business expands further internationally, you could assume that we will want to continue to scale the sales channel. And, you know, we've, we've talked about building a hundred million dollar business here. I think you said, heard me say in the call a business well over 100 million. I don't want to put a number on that right now, but I, All systems are go here for us to build a very, very large business in this space. And, you know, we love the financial metrics associated with it. And we see very little resistance to us continuing to do that over the course of the next several years. And it's just this is a big new TAM with a big new growth opportunity all the way around that should drive really strong top line growth for us for the next several years. Great. Thank you.
spk14: Thank you. Our next question comes from the line of Sam Brodowski with Truist Securities. Your line is now open.
spk12: Hey, guys. Can you hear me okay?
spk06: Loud and clear, Sam.
spk15: Great. Thanks for taking the question, and congrats on a solid start to the year. I just want to start off a higher-level question and appreciate the commentary on where system capacity is back at. Can you just remind us what's contemplated in guidance as it relates to capacity coming back online, and if there's any sort of backlog component in your estimation out there in the market that could potentially come into the volumes this year.
spk05: Yeah, I don't think we try to anticipate dramatic increases in capacity in our guidance. So it's pretty much what we see today is what we try to use to forecast and include in the guidance. And we honestly, other than a little bit of carryover from RSV December into January, don't feel that there's some huge pent-up demand that's going to flow through the system in our guidance either. Great.
spk15: to EOS? Just as we think about that opportunity, how quickly do you think the new products could see uptake there? Is it going to be similar to what we saw with Apifix where data needs to mature a little bit before you can see broader adoption? Or do you think there's room for that to potentially adopt even more quickly? Thanks.
spk07: Yeah, that's a really good question. So I think with the EOS and what's different about EOS than Apifix is that know the apophix surgery this non-fusion spine surgery is a procedure that you know not every surgeon does you know this is not this is asking surgeons to do something different within their practice that they currently do the fact remains is that a child with early onset scoliosis young kid that's having you know substantial difficulties there really isn't a non-surgical treatment option available these are procedures that are happening and surgeons are struggling right now to find adequate technologies to do those procedures, perform those procedures. So I think technology wins in this space. There's a great hunger from the pediatric orthopedic community to have technologies that can benefit these kids. And a lot of times surgeons are forced to use kind of last resort types of products. So these procedures are happening. And so I think, you know, if we have better technology, which we believe we will, and then we can round that technology out with three different products, we think really the three products you would need to take care of this very tough set of indications gives us a real distinct competitive advantage. And we do think that the uptick can be really strong with these product lines. And again, I think as much as the uptick in the EOS revenue, it also places the company in, I believe, a fairly prestigious spot in the minds of our customers that say we're willing to take on the extremely difficult things. that the majority of ortho is just not taking on. I mean, these are pretty fairly rare conditions, but they're very complicated, and surgeons haven't historically had great partnerships to take care of these kids. So we think that kind of creates, again, another halo around the business, gives us an opportunity to help more kids, but also will probably drive the usage profile of the balance of our other products.
spk12: Thank you.
spk14: And I'm currently showing no further questions at this time. I'd like to hand the call back over to David Bailey for closing remarks.
spk07: Thank you. Well, I'd like to thank everybody for joining us today. We've got an exciting week here at ePosna. I think this will be the largest meeting of the pediatric orthopedic community in history. And so we're excited to get out there and meet with customers, show off what we've done, and just no better place to talk about you know, a fantastic quarter for us and all the momentum we have heading into the balance of 2024. So appreciate everybody being on the call. Great questions. And we'll look forward to reporting on how things go as we progress. Take care.
spk14: This concludes today's conference call. Thank you for your participation. You may now disconnect. you Thank you. Thank you. Thank you. Good morning, and welcome to Orthopediatrics Corporation's first quarter 2024 earnings conference call. At this time, all participants are in a listen-only mode. We will be facilitating a question and answer session towards the end of today's call. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Tripp Taylor from Gilmartin Group for a few introductory comments.
spk19: Thank you for joining today's call. With me from the company are David Bailey, President and Chief Executive Officer, and Fred Height, Chief Operating and Financial Officer. Before we begin today, let me remind you that the company's remarks include forward-looking statements within the meaning of federal securities laws, including the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to numerous risks and uncertainties, and the company's actual results may differ materially. For a discussion of risk factors, I encourage you to review the company's most recent annual report on Form 10-K, which was filed with the SEC on March 8, 2024. During the call today, management will also discuss certain non-GAAP financial measures, which are supplemental measures of performance. The company believes these measures provide useful information for investors evaluating its operations period over period. For each non-GAAP financial measure referenced on this call, the company has included a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures in its earnings release. Please note that the non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for orthopediatrics financial results prepared in accordance with GAAP. In addition, the content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, today, May 7, 2024. Except as required by law, the company undertakes no obligation to revise or update any statements to reflect events or circumstances taking place after the date of this call. With that, I would like to turn the call over to David Bailey, President and Chief Executive Officer.
spk07: Thanks, Trent. Good morning, everyone, and thank you for joining us on our first quarter 2024 conference call. As we start all earnings calls, I'd like to begin by highlighting that we helped a record 27,600 kids in the first quarter of 2024. This remarkable 47% year over year growth is the metric we're most proud of out of all of the stuff we'll share with you today. It embodies our fundamental commitment to helping children and demonstrates our ability to continue to expand our reach and create a more significant impact for children worldwide. So today, we're excited to join you live from just outside of Washington, D.C. at the EPOSNA Conference, where POSNA and EPOS are collaborating to host a joint annual meeting. This is the largest pediatric orthopedic conference in the world. And once again, Orthopediatrics is the leading sponsor of this event. The shared mission across our three organizations will be advanced through clinical data presentations, and educational sessions highlighting the most cutting-edge pediatric orthopedic treatments and technologies. We're looking forward to connecting with our customers and colleagues this week, and there is no better place to deliver our exciting business update. Orthopediatrics is off to a great start in 2024, generating first quarter revenue of $44.7 million, representing growth of 41% compared to the first quarter of 2023. Driven by strong performance across the businesses, we continue to demonstrate robust top-line growth, maintain healthy margins, and outperform our adjusted EBITDA expectations. The execution of our business plan is delivering both financial results and progress on our strategic initiatives. Looking closer at the quarter, after an initial RSD spike seen in early January, revenue and surgery scheduling quickly bounced back. Children's hospitals have learned to manage RSV waves efficiently and effectively mitigate disruptions previously seen. Overall, improvements in the surgical environment are tracking our expectations. Hospitals are now better staffed, and the training of new associates is contributing to improved efficiency. Improvements continue every month, and by our estimations, we're approximately 95% back to normal levels. Given the seasonality of our business, The improved children's hospital's capacity will be tested in these critical summer months. Throughout the next few quarters, we will continue to monitor this progress closely. However, our confidence continues to increase that this headwind will have less and less of an impact moving forward toward a completely normalized state. We've built a business with a highly diversified portfolio that surrounds our surging customers with high-technology products that continue to take market share and drive orthopediatrics growth. During the quarter, the global trauma and deformity, international scoliosis, and our newly formed and rapidly expanding specialty bracing business, or OPSB, were all particularly strong. First quarter, global TND was very strong, with 42% year-over-year growth led by sales of Pega products, PNP Femur, Orthex, early sales of PNP Tibia, and growth within the OPSB franchise, as well as the addition of Boston O&P's T&D product sales. P&P Tibia demand continues exceeding expectations, and DF2 revenue has started strong. In addition, total surgeon users of XFIX increased by 29% in the first quarter, and total accounts increased by 37%. We believe these numbers imply strong quarters are ahead of us. Looking at our international business, We reported strong overall growth of 33%, led by a rebound in scoliosis and very strong sales of TND, with X6 at 59% growth and PEGA at 152% growth. Operations commenced at our recently established German headquarters, which is improving customer service and increasing surgeon access to orthopediatrics products across the country. We are already seeing a return on this investment, as the German business grew 22%. We're also seeing very high growth in Canada, where recent product registration and our account conversion strategy have been extremely effective, leading to large share gains in some of the country's largest, most prestigious children's hospitals and global teaching institutions. In addition, the macro environment in Brazil is improving. This momentum internationally is expected to continue throughout 2024. Scoliosis revenue had substantial impact 44% growth, led by domestic apathics, international sales in Europe and Latin and South America, along with another quarter of share-taking in our Fusion franchise, as well as the addition of Boston O&P Scoliosis custom bracing product sales. We expected the OUS Scoliosis to rebound aggressively in 2024 and to act as a tailwind, and this is exactly the trend we're seeing to start the year. OPSB contributed to growth in both the T&D and scoliosis businesses as a result of Boston O&P acquisition, coupled with increased sales from products unrelated to Boston O&P clinics, such as MDO, DF2, Ora Medical, and Rhino. Increases in OPSB sales continue to rise as we hire additional sales staff exclusively focused on this franchise, and we are confident that as we build this business, there is a massive opportunity to capture growth. The various levers driving the next phase of orthopediatrics growth and profitability are becoming more visible, and we remain quite bullish about our prospects for 2024 and beyond. For the remainder of the year, we're focused on continuing legacy product growth, launching several key new organic products, expanding Pegasales, capitalizing on normalization in international markets, publishing positive longer-term Appifix data, an execution on OPSB, and an early start in digital healthcare. The continued advancement of our strategic initiatives paired with our strong financial position will enable us to execute our long-term goals. With a solid start for the year, we are raising our revenue guidance for full year 2024 to $200 to $203 million, representing growth of 34 to 36%. The plethora of growth drivers outlined have positioned this business to continue growing on the top line while improving profitability on our way to cash flow break even sooner.
spk12: Moving to our revenue segments.
spk07: In the first quarter of 2024, we generated total trauma and deformity revenue of $33.3 million, representing growth of 42% compared to the prior year period. This quarter saw strong performances from PEGA products, trauma, specifically P&P Tibia, X6, and OPSB, as well as the addition of Boston O&P T&D product sales. Our prior investments in set allocations are generating a return and driving meaningful share gains for the T&D business across the entire breadth of products, specifically Pega, which once again grew nearly 50% globally. Sales of Pega continue to be better than we ever expected. As we more deeply penetrate our U.S. accounts, with the full Pega product portfolio, and we ramp international sales. Now that the distributor and agency transition is complete OUS, Pega will likely to continue this trajectory globally in 2024 and for the foreseeable future. Excitedly, the full US market release of PMP Tibia and Gyro are underway, with several sets expected to arrive at accounts in the second quarter and every quarter thereafter for the next several quarters. The full market release of DF2 is also underway, and there is extremely high demand for this product, and it's helping grow OPSB sales. These products are great additions to our portfolio and will create an immediate impact. Product portfolio expansion remains a top priority for the business. We seek to surround our surging customers with everything they need to treat each patient and treat more children. Orthopediatrics is building a dominant share position across our entire T&D portfolio. Each quarter, more customers are using more of our products, driving increased market share. Adding new high technology products like Pega helps advance the key account conversion strategy. The T&D business is increasingly well positioned to continue to deliver sustainable growth for the next several years. On the R&D side, there are several exciting products within the surgical side of our T&D business. We're making great progress developing our entirely new Pediatric Plating Platform, or P3, which we expect will be world-class and spawn further share-taking opportunities for us within our plating franchise. We've also made solid strides on new external fixation devices that will continue the growth trajectory of our X6 franchise. Further, there will be several new CE Mark products that are positioned to launch in the EU market in the coming year to 15 months. The orthopediatrics non-surgical specialty bracing business, or OPSB, is performing extremely well, and we continue to view this franchise as a significant opportunity to help more kids. Before diving into some of that progress, I want to reiterate the OPSB opportunity briefly. In addition to furthering our strategy to provide pediatric orthopedic surgeons with everything they need to treat children, we see this as another opportunity for market dominance as we scale a historically fragmented market to become the clear-cut leader. 80% of pediatric orthopedic care is delivered outside of the operating room, and we estimate the U.S. non-surgical specialty bracing market is at minimum $775 million in total and conservatively a $500 million opportunity within the top 300 children's hospitals. From a business model's perspective, importantly, these custom-fit devices do not require the upfront capital investment in consigned inventory or instrument set. As mentioned on our previous calls, we continue to successfully execute a build aggressively strategy in OPSB and anticipate it to grow very rapidly in the coming several years. OPSB is in the early innings of what we believe can be a business well in excess of $100 million in the coming years. The planned Salesforce expansion, product developments, and the addition of new clinics will scale this business rapidly. Progress expanding the sales force and integrating our specialty bracing products with Boston's are already contributing to growth. Our existing R&D pipeline will support launching four to five new products within the OPSV business every year. Lastly, we've identified several new clinic opportunities and expect these to have a major impact as early as next year. Moving on to the scoliosis business. In the first quarter of 2024, we generated revenue of $10.2 million, representing global growth of 44% compared to the prior year. This global growth was led by a return in international sales in Latin and South America, new business in Europe, and strong Appifix growth, as well as the addition of Boston O&P Scoliosis custom bracing product sales. First quarter domestic sales increased by 38%, led by the addition of Boston Brace from the Boston O&P product portfolio. We are proud to add the most studied and utilized scoliosis brace in the world, and a product that is considered to be the premier system for non-operative treatment of scoliosis and kyphosis to the OPSB portfolio. We're pleased with the rebound from the international scoliosis business, which outpaced our domestic business, generating 114% growth. We expect to see a continuation of strong international growth, coupled with a robust summer surgery schedule in the coming quarters. The increased number of total response users over 2023, earnouts on 70 units placed in 2023, continued apathics growth, improvements in South America, and our European launch, all together keep us bullish on 2024 scoliosis growth. The scoliosis R&D pipeline is continuously progressing, and the funnel is rich with highly novel technologies that solve major unmet needs for our customers, specifically for patients with early-onset scoliosis, a category in which we have never had products before. In the first quarter, we launched the first of three products in the EOS space. The first surgeries with response rib and pelvic were completed in the first quarter, producing excellent results. we've made great progress with our new growing spine system for EOS called VertiGlide and hope to have FDA approval secured in the second half of 2024. Further, the FDA recently classified our electromechanical growing spine rod, ELE, with the breakthrough device designation, both a major milestone on our way to FDA approval and a strong endorsement of ELE's potential for patients suffering from EOS. Lastly, Substantial progress has been made on the development of our next generation fusion system. The next 18 to 24 months will be the most prolific period of new product development and launches in OP scoliosis history, transforming the already impressive product portfolio into the most substantial offering available to surgeons treating pediatric scoliosis. Moving on to international. Overall, international growth improved substantially compared to the prior quarter, generating revenue of $10.4 million, delivering 33% year-over-year growth. This major rebound was supported by a return to normal ordering patterns for Scoliosis products in South America, the launch of Scoliosis in Europe, Pega products, and general demand across the entire T&D portfolio. The international growth seen this quarter is very encouraging. As I mentioned earlier, we are seeing meaningful traction within several of our core international markets. The results we've seen in Germany are particularly pleasing as we begin to reap the benefits of our investment in building a direct sales channel and local customer service. As we await the notified body audit to finalize our EU MDR status, we are thrilled about all the progress we've made internationally and that 2024 has started off on such a strong footing. We expect completion of our audit in the second half of 2024, enabling the potential launch of several new products in Europe shortly thereafter. Given the general lack of new pediatric orthopedic product launches in Europe over the past four to five years, it is particularly impressive that we've made so much headway and have many more opportunities in front of us. Overall, the international business is set up nicely. We believe that the first quarter represents a great start to an improved 2024. That brings us to surgeon training and education. Since inception, facilitating educational opportunities for the pediatric orthopedic community has been a foundational component of orthopediatric strategy. That's why we are live from the EPOSNA today, and we look forward to updating you on how productive and impactful this meeting will be for the pediatric orthopedic community. Back in April, the company was again a lead sponsor of ICSS, a meeting that offers a comprehensive program of lectures given by an outstanding international faculty and didactic cadaver labs focused on the cervical spine, lumbosacral junction, neuromonitoring, and various aspects of scoliosis. This interactive forum was a great opportunity for us to engage with pediatric orthopedic fellows and attending surgeons and provide training on the latest technologies and surgical techniques. We highlighted response and the new pelvic fixation system at this year's meeting. In the quarter, we conducted a total of 46 unique learning experiences, highlighting over 162 different product touches, including labs, workshops, and sawbone stations, and we reached over 1,100 healthcare providers and other staff members. As we continue advancing our ongoing commitment to training the next generation of pediatric orthopedic surgeons and leading innovation, in our subspecialty around the world. Lastly, because of the continued focus on our people and culture building, I want to again highlight that for the eighth time, Orthopediatrics was named as one of the best places to work in Indiana. We are committed to fostering a culture that is positive, engaging, and allows our associates to do their best work. This has become a key aspect of our competitive advantage and continues to expand our ability to help more kids around the world. With that, I'll turn the call over to Fred to provide more detail on our financial results. Fred?
spk05: Thanks, Dave. Our first quarter 2024 worldwide revenue of $44.7 million increased 41% compared to the first quarter of 2023. Growth in the quarter was driven primarily by strong performance across global trauma and deformity, international scoliosis, and OPSB as well as the addition of Boston O&P. U.S. revenue was $34.3 million, a 44% increase from the first quarter of 2023. Growth in the quarter was primarily driven by our trauma and deformity product lines, scoliosis, and OPSB as well as the addition of Boston O&P sales. We generated total international revenue of $10.4 million, representing growth of 33% compared to the first quarter of 2023. Growth in the quarter was primarily driven by trauma and deformity, scoliosis, and OPSV. In the first quarter of 2024, trauma and deformity global revenue of $33.3 million increased 42% compared to the prior year period. Growth was primarily driven by strong growth across numerous product lines, specifically arcane-related screws, PMP femur, PD plates, external fixation, and the PEGA systems, as well as the addition of Boston O&P trauma and deformity correction product sales. In the first quarter of 2024, scoliosis revenue of $10.2 million increased 44% compared to the prior year period. Growth was primarily driven by increased sales of our Response 5560, ApiFix systems, and revenue generated from 7D technologies, as well as the addition of Boston O&P Scoliosis custom bracing product sales. Finally, sports medicine other revenue in the first quarter of 2024 was $1.2 million, compared to $1.1 million in the previous year period. Turning to set deployment, $4.3 million of sets were consigned in the first quarter of 2024, compared to $3.0 million in the first quarter of 2023. The increase was driven by the strategic decision to bring in inventory earlier in the year and deploy a greater percentage of the annual sets prior to our busy summer months. Touching briefly on a few key metrics. For the first quarter of 2024, gross profit margin was 72% compared to 75% for the first quarter of 2023. The decrease in gross profit margin was driven primarily by increased international set sales in the first quarter of 2024, as well as less purchase price variance released in the first quarter of 2024 compared to 2023. Total operating expenses increased $9.7 million, or 30%, to $41.9 million in the first quarter of 2024. The increase was mainly driven by incremental personnel costs associated with increased headcount, increased commissions, and the addition of the Boston O&P acquisition. Sales and marketing expenses increased $1.6 million, or 13%, to $14.2 million in the first quarter of 2024. The increase was primarily driven by increased sales commission expense, with a limited increase coming from the addition of Boston O&P acquisition. General and administrative expenses increased $7.6 million, or 44%, to $24.7 million in the first quarter of 2024. The increase was driven primarily by the addition of Boston O&P acquisition, as well as resources to support the continued expansion of our business and increases in non-cash expenses such as stock compensation, depreciation, and amortization. Research and development expenses increased $0.6 million, or 23%, to $3.0 million in the first quarter of 2024, due to the incremental product development and the addition of personnel to support the future growth of the business, as well as the addition of the Boston O&P acquisition. Total other expense was $0.6 million for the first quarter of 2024, compared to $1.2 million of other income for the same period last year. In the first quarter of 2023, we recognized a $0.6 million favorable adjustment to contingent consideration that did not repeat in the first quarter of 2024, as well as increased interest expense from our $10 million mid-cap loan. Adjusted EBITDA loss was $1.1 million in the first quarter of 2024, and this compares to a loss of $2.1 million in the first quarter of 2023. We ended the first quarter with $49.7 million in cash, short-term investments, and restricted cash. Cash usage in the first quarter of 2024 includes $22 million paid for Boston O&P, increased set deployment, as well as increased inventory to support future set deployments. With our current cash position, as well as our debt facility, we are well capitalized to continue to execute on our long-term strategy. Given our strong balance sheet, positive annual adjusted EBITDA, our line of sight to cash flow breakeven, and the addition of Boston O&P, we are in a position of tremendous strength. Turning to guidance, we are raising our expectation for full-year 2024 revenue from the previously announced $197 to $200 million up to $200 to $203 million, representing year-over-year growth of 34% to 36%. We continue to expect to generate between $8.0 to $9.0 million of adjusted EBITDA in 2024. Additionally, We continue to expect less than $20 million of new sets deployed in 2024. This represents our continued focus on driving the business to cash flow breakeven sooner rather than later. As mentioned, this year, we plan to deploy sets earlier in the year compared to prior years. I will now turn the call back over to Dave for closing remarks.
spk07: Thanks, Fred. Looking at the first quarter, we are extremely proud of how we've started 2024 and are confident that we will continue this momentum into the remainder of the year and beyond. We continue to capture share across the entire business, record robust top-line growth, maintain healthy margins, and outperform our EBITDA expectations. We will continue to move toward profitability growth and cash flow breakeven as we execute our strategic initiatives to drive value and capitalize on our opportunities. 2024 will be a tremendous year for orthopediatrics, and I look forward to updating you again soon. In closing, I'd like to thank our surgeon partners, my OP associates, our investors, and all of the innovators in pediatric healthcare for standing together to help kids. Operator, let's open the call for Q&A.
spk14: Thank you. As a reminder, to ask a question, please press star 11 on your telephone and wait for your name to be announced. To withdraw your question, please press star 11 again. Please stand by while we compile the Q&A roster. Our first question is from the line of Ryan Zimmerman with BTIG. Your line is now open.
spk18: Good morning and congrats on a strong start to the year here. I want to ask about guidance. Two-part question here. You beat by about three and a half million. You're raising by three at the midpoint. Just curious if you're seeing anything kind of ahead that you want to you're a little cautious about, or maybe reserving that incremental half million. And the second part is, you know, you are passing through that 3 million adjusted EBITDA guidance to stay in the same. So just talk to us about kind of that flow through on higher revenue into the business and kind of what you're putting that to work on.
spk05: Yeah. So first of all, we're obviously very excited about 41% growth in the first quarter. It's a great start to the year and sets us up very nicely. We had some RSV in late December, a little bit of it in January, and then I think some of that December got pushed into January, which helped pretty strong January to start the quarter, which is great to see. The wild card for us, as you know, Ryan, is always the summer months, right? June and July are typically the dramatically larger months for us throughout the year, and how those summer months surgery seasons play out is really unknown until we get there. And so I think that's probably where the half a million dollars maybe is on the revenue as far as why it didn't flow through for the full year. And it's really the only thing that gives us pause, if you will, on increasing it further at this point. Okay.
spk18: And the EBITDA guide relative to the BEAT, are you putting that back in the business for us?
spk05: Yeah, the EBITDA number, the range is pretty wide. And again, the summer months are so large, that's when so much of it drops through. And so as you saw in the first quarter, it was negative 1.1, basically on or maybe a little better than our expectation. But we want to wait and see what the summer months look like, and then we can increase that as we move throughout the year. Got it.
spk18: And then just last one for me, you know, Boston O&P looks like it's been, you know, a real good contribution and asset to bring in. Dave, love to hear your thoughts on clinic development. It's really the longer-term plans of what you can do with Boston OMB relative to your broader surgical customer base.
spk07: Yeah, good question. We see, I think you've heard me say this before, Ryan, the volume of inbound interest we've gotten from our customers related to the Boston L&P acquisition is probably as great, if not greater, than any other transaction or product we've done up until this point. So there's clearly a serious need out there to have a company focused exclusively in this bracing space and providing that service that Boston has done so well in about 15 institutions in the Northeast. And we want to obviously expand that to everywhere in the United States. Huge opportunity to do that. You know, it's going to take us some time. I think by the fall this year, we'll probably be able to give some guidance as to what we think the pace is going to look like in terms of clinic expansion. But there is no shortage of opportunities for us from a clinic expansion standpoint. We have kind of an outpouring of ask here from a number of locations, and it's just going to take us some time to spin some of those things up. It's possible that we'll have some of these deals done and some clinics moving here by year end, but we're not forecasting that. We do have the opening of our first clinic inside Children's National or Nationwide Children's in Columbus, which is, I believe, the highest volume children's hospital in the United States. So that should start here in the next few months. So really positive in terms of the long term. I think what we were really most pleased to see here is the fact that As we've added the sales channel, and then we've added a number of products to the MDO portfolio since the acquisition a few years ago, it's great to see all of those products already contributing to revenue growth. Not the clinic side of this stuff, but we've talked about a three-part strategy. Number one of sales channel and selling the products we have. Number two, accelerating R&D, which we're definitely doing on pace to have four or five new products a year. And then lastly, clinic expansion and to see the first two of those portions of our strategy already start to contribute and then to think that, you know, we have this huge TAM expansion opportunity, really large growth opportunity that should really kick in in 2025 when we start to realize the benefit of clinic expansion. It's just really exciting. I think it's given us a reason to be very bullish.
spk18: Sounds good. Thanks for taking the questions, guys.
spk07: Thanks, Ryan.
spk14: Thank you. Our next question comes from the line of Matthew O'Brien with Piper Sandler. Your line is now open.
spk05: Morning. Thanks for taking the question. Just maybe to start with, oh, morning. On the Boston O&P contribution, you know, I know I think you guys had mentioned it being about a $25 million business roughly historically, and I think that's kind of what we were modeling this year. Is the increase that we're expecting in the guidance for the year, just all Boston O&P related, the extra 3 million bucks really related to that. So it's more like 28 million. So you're kind of running ahead of schedule or how do we kind of frame up how well Boston O&P has done so far on its own? No, I wouldn't assume that at all. I think you can assume that it's similar to historical levels. I think as we've mentioned in the past, about 23% of that 25 million typically falls in the first quarter. 25% in the second and third quarter and 28% in the fourth quarter. But the extra $3 million is not from Boston and very pleased with the legacy business, if you will.
spk07: Yeah, Matt. I mean, we see growth across every segment at this stage. I mean, it's just really good to see really positive momentum. I do want to specify that we are seeing, you know, above average growth in OPSB, but we've been doing that for a long time, right? I mean, we have taken, ever since we took on the MDO product portfolio on the Clubfoot side and then added products last year, that business has been growing in excess of 20% really since the acquisition. And we're seeing more of that. And so the OPSB, let's say minus the Boston clinics is performing extremely well. And it's certainly adding all those product lines to the T&D growth. So yeah, from that perspective, let's say the non-Boston component of OPSB, really pleased for what we're seeing there. But listen, this is a growth story that's going across every product line right now. Okay.
spk05: Okay. That's great to hear and super encouraging. Just maybe back to that other point, I'm assuming it's too early to be getting any kind of halo effect from Boston OMP, but the PEG and numbers and Some commentary about APISX and other areas seem like they're kind of, you know, the momentum there is extremely strong. So I'm just curious about just the core business or the more organic historical business, where some of that growth is coming from and the durability of some of that growth, especially PEG. I mean, I know you're not going to grow 150% every quarter with that thing, but, you know, just some of the durability that you're talking about now in the more, you know, traditional orthopediatrics franchises would be helpful. Thanks.
spk07: Yeah, I think what we're seeing, you know, first on the implant side of trauma limb deformity, I mean, it's no secret that we've put out a lot of inventory over the course of the last few years. It's also no secret that some of that inventory utilization has been maybe stifled a little bit just because of pure throughput inside children's hospitals. And so I think what we're seeing is a combination of the fact that we've landed a lot of inventory and we're starting to see a normalization almost back to normal in terms of the surgical market. And so we're seeing efficiencies in that inventory and you might assume that we're being pretty aggressive in terms of wanting to pull up some of that product launch into the first half of this year because we're starting to drive real efficiencies and see real growth from the inventory that we put out in 2022 and especially 2023. So it's good to see a lot of that legacy growth come because obviously we were betting on that when we put out that volume of inventory. I would argue that You know, we're obviously seeing, you know, really the first returns of a lot of inventory of Pega. And so still seeing great growth domestically. I think it was about 50% globally. So stronger international, much smaller business for us. But now that we have Pega in all of our agencies and converted to all our distributors, I mean, we do expect to see pretty strong growth from Pega outside of the United States for a long time. I would also say, you know, PMP Tibia is performing better than we had expected previously. Admittedly, I think we're almost to our annual sales growth number forecast on PMP Tibia now through April. And so that's a pretty strong indicator that that product is going to work for us. And I think it is also driving a bit of a rebirth in the usage profile of PMP femur, which is our largest trauma product. So those things really cranking. And then, I mean, the numbers don't lie in terms of our ortho or the orth X growth. You know, the X6 portfolio has grown ever since we made that acquisition now, what, three and a half years ago. And to see three and a half years later, that business growing at that rate. And it's still really now just starting to catch its stride outside of the United States. You know, we think we're a top two player in children's hospitals, at least in the U.S. and the X6 market. And so, man, all of those things are working for us. And that's a good momentum as we think about heading into the balance of the year. Last thing, Apifix is, I think we're starting to benefit from some better data. We're going to have longer term and better data going forward. But Apifix is cranking and, you know, the halo was Apifix 70 drive and response sales. And that's what we've been saying for a long time. And I think the beat continues there. And as surgeons see us making investments in OPSB, surgeons see us doing the deal with Boston. I think it gives people a sense of permanence for our company. They can trust that we're going to be around a long time. It also gives people a sense of, wow, these guys are putting their money where their mouth is, that they're very serious about continuing to advance the entire field of pediatric orthopedics. And of course, that creates a big halo across the whole business, not just a few products.
spk13: Got it. Thanks so much.
spk14: Thank you. Our next question comes from the line of Rick Wise with Stifel. Your line is now open.
spk09: Good morning, gentlemen. A couple things from me. Very exciting quarter, obviously. But getting into the weeds a little bit, Fred, maybe you can help us talk us through how to think about gross margin progress for the year, sort of from a quarterly perspective. I heard what you said about some of the gross margin, if you will, mixed pressures in the quarter that took it a little lower than we were thinking. The OUS set sales and the purchase price variances, et cetera. Can you help us understand how that plays out over the course of the year? Does it step up sequentially? Are we understanding in the second quarter, does it step up sequentially in some kind of way that sort of gets it back more to the 74%, 5% range? Just help us by quarter and the implications for the year now.
spk05: Yeah, absolutely. So the gross margin rate really varies a lot based on volume. And so over the last many, many years, the third quarter is typically the highest gross margin rate. I think it was like 77% last year. The second quarter is typically the second highest quarter. And then with the first and the fourth quarter revenues being much smaller, obviously, than those two quarters in the middle, the margin is typically a little lower in those quarters. So, yeah, I would expect an increase second quarter compared to first quarter, and then possibly another increase third quarter compared to second quarter.
spk09: So still getting to that mid-70s. kind of area for the year despite the start or no? Yeah.
spk05: You're still comfortable with that? Yes. I think I mentioned 475 on the call last time.
spk09: Great. Turning to the pipeline, obviously, Dave, you're talking about a really exciting pipeline. I can tell you're excited about it. Maybe talk to us about a couple of things some of the organic product launches in a little more detail, which ones you'd have us focus on most and just a little more sense of timing. You highlighted a couple of them, but maybe dig into a little more. And as part of that, why this electromechanical growing rod opportunity is such a big deal and what the breakthrough designation might mean for launch expectations. A lot in there, but if you could just break some of that down.
spk07: Great. Yeah, sure. So I think the near-term opportunity, right, is with products that we just had launched here or kind of kicked off in Q3 and Q4. So PMP Tibia, as I mentioned earlier, really doing well. I mean, we have, I don't know, Fred, 15% of the sets that we'll have out on PMP Tibia. I mean, maybe 10%. So to see it performing the way it's performing with a volume of inventory that hasn't even been launched, I think that's going to be a story for us. Gyro, certainly a story for us. DF2 on the OPSB side, that was a product that we developed for fracture care for patients really under the age of four that has been well-received. So those products, kind of the here and now, we've got them in our hands. They're going well. Started doing first cases with, as I said, our first EOS product line. And you hear us talking a lot about the EOS space. That represents about 15% of scoliosis procedures. And up until this point, we've never had a product in that space. So, you know, three different products, the first of which we talked about the response ribbon pelvic that just launched, and we have sales going on and procedures going on with that. Then this verticalized device. which is another very substantial, I think will be a strong revenue producer for us. Hopefully we can get it out in the second half of this year. And then Ellie, as you mentioned, which is the device that was this electromechanical growing rod, just received breakthrough device designation. I mean, our strategy in the early onset scoliosis space is not to provide the customer with a single solution. Most of the kind of adult ortho or adult spine companies may have a single product line for early onset scoliosis. Again, true to a form, we want to surround the surgeon with everything they could use across that very, very complicated set of indication. And so very excited. I think all of that creates, again, a seriousness in our product portfolio that requires the top institutions in the world to very seriously because we would be the only company in the world with that type of portfolio for that really difficult set of circumstances. The FDA, the breakthrough device designation essentially allows us to have a direct one-on-one with FDA to process the approval of this device. Certainly, there's no guarantee, Rick, that it gets approved, but based on our testing and based on, you know, the capacity to have these one-on-one discussions with FDA, and get a very clear sense of what FDA wants to see from us to get this device approved, it gives us a lot of confidence that we're going to be able to do that. And I think, you know, it's the first time in our company's history, and maybe that's why I'm personally so excited about this. It's the first time in our company's history where we've ever had a technology that was deemed so significant to the healthcare of pediatric patients that it got treated this way by the FDA. And so I think, you know, I can't imagine a stronger indication of the need profile for a device like this. And, you know, for those of us who have been around a while, there's a certain, well, it's just a realization of some of our dreams to be able to get involved in some, not just shaping kids' lives or helping kids improve life, but in some of these procedures, you know, these are potentially life-saving surgeries. And that's, again, I just think it's a real accomplishment for the company. And we think within the next year or so, that device can be out and be implanted in children, and that's a real breakthrough for us.
spk08: That's exciting. Thanks for all the color. Thanks, Ray.
spk14: Thank you. Our next question comes from the line of Mike Madsen with Needham & Company. Your line is now open.
spk02: Yeah, thanks. So I wanted to ask about Europe. I think there was some commentary that you're expecting some new product clearances there, You mentioned an audit or something. Can you just provide a little more detail on what's happening there? It sounds like it could be meaningful in terms of the number of new products you're expecting.
spk07: Yeah, great question, Mike. So basically, you can think about our product portfolio and how it's developed over the course of the last four years and assume that almost none of those products that we've developed, particularly organically, none of those products have hit the European market yet. And so, you know, if you just look at the slide deck and see how much we have developed and put out into the U.S. market and certain other markets outside of the U.S., most of that hasn't hit Europe, yet we're still growing very rapidly in the European market. So you can kind of think of this as really a massive opportunity for us to launch, you know, several new brands that are new to Europe. You know, here we're at the European, at the combination meeting between the EPOS, the European Pediatric Orthopedic Society, and the Pediatric Society of North America here in DC. I mean, a lot of these surgeons have seen these products. They'll certainly see them exhibited here, but they haven't had access to those products in markets like Germany, UK, Ireland, Italy, France, Spain. And so this is a big deal for us when we can get this approved. We are ready for the EUMDR audit. Our technical files, everything is updated. We're ready to roll. It's just a question, frankly, of getting notified body into our offices. They're backed up with, you know, all kinds of these audits. And so as soon as we get that audit done and we will be ready to start launching these products, I'm not certain we can put a date. You know, is it November or December or early next year? That's why we've kind of said 12 to 15 months. But when it happens, it's a big deal for us. And I think it represents, you know, the launch of almost four or five years of U.S. products into the European market.
spk02: Okay, thanks. And then I know that you don't really disclose your sort of organic growth, but, you know, if we assume that Boston O&P was sort of like five and a half million, it implies about 24% growth for the non-O&P business. So, you know, it seems like it's safe to assume your organic growth was probably over 20%.
spk07: I mean, is that reasonable? I'd say that's an extremely reasonable assessment, Mike. Yeah.
spk02: Okay.
spk07: All right. Thank you.
spk14: Thank you. Our next question comes from the line of Dave Turkley with Citizens JMP. Your line is now open.
spk17: Hey, good morning, guys. Sorry, I've been bouncing around a little, so I hope I asked something that hasn't been asked. But you mentioned, I think, that you're going to hire some staff for Boston.
spk16: And I was just curious, could you just refresh our memory in terms of
spk17: The footprint that you have today, and I think you even said that you think that you could build that to $100 million. What kind of headcount came with them, and how many people do you need to add, and how quickly can you do that?
spk07: Yeah. So what we've been talking about, Dave, is just the scaling of the sales force. So when we acquired Boston and MD Orthopedics, You know, literally there was no direct sales staff. We had a couple people that were kind of sales managers, and we have some really great folks that have been helpful, you know, kind of one-person teams really leading in the United States and then a few people outside of the United States that have done great for Boston and for particularly MDO. And, you know, now we're trying to get those people and others an actual sales force. And so the aspiration here in 2024 was to have about 20 people added within the sales channel And we want to partner those people with our current US and international distributors. We don't want these people to be entirely separate. So they'd show up on the doorstep of a customer who they don't know. Obviously we have very close relationships with really every pediatric orthopedic surgeon around the world. And so we want to be able to leverage, you know, our relationship and the fact that they know orthopediatrics and then bring some people into the sales channel that focused exclusively on the non-operative side. You know, that aren't obligated to stand in the operating room and work with surgeons all day long, but certainly can work in their clinics. And so that's what we're really talking about. We have added, I would say, I don't know for sure, but I think we probably added the majority of those salespeople already. And so those costs have started to figure into our P&L already. And obviously, we've got that forecasted for the balance of the year. As that portfolio expands and clinics expand and maybe even our business expands further internationally, you could assume that we will want to continue to scale the sales channel. We've talked about building a $100 million business here. I think you heard me say in the call a business well over $100 million. I don't want to put a number on that right now, but I All systems are go here for us to build a very, very large business in this space. And, you know, we love the financial metrics associated with it. And we see very little resistance to us continuing to do that over the course of the next several years. And it's just this is a big new TAM with a big new growth opportunity all the way around that should drive really strong top line growth for us for the next several years. Great. Thank you.
spk14: Thank you. Our next question comes from the line of Sam Brodowski with Truist Securities. Your line is now open.
spk12: Hey, guys. Can you hear me okay?
spk06: Loud and clear, Sam.
spk15: Great. Thanks for taking the questions, and congrats on a solid start to the year. I just want to start off a higher-level question and appreciate the commentary on where system capacity is back at. Can you just remind us? what's contemplated in guidance as it relates to capacity coming back online, and if there's any sort of backlog component in your estimation out there in the market that could potentially come into the volumes this year.
spk05: Yeah, I don't think we try to anticipate dramatic increases in capacity in our guidance. So it's pretty much what we see today is what we try to use to forecast and include in the guidance. And we honestly, other than a little bit of carryover from RSV December into January, don't feel that there's some huge pent-up demand that's going to flow through the system in our guidance either.
spk15: Great. to EOS? Just as we think about that opportunity, how quickly do you think the new products could see uptake there? Is it going to be similar to what we saw with Apifix where data needs to mature a little bit before you can see broader adoption? Or do you think there's room for that to potentially adopt even more quickly? Thanks.
spk07: Yeah, that's a really good question. So I think with the EOS and what's different about EOS than Apifix is that know the apophix surgery this non-fusion spine surgery is a procedure that you know not every surgeon does you know this is not this is asking surgeons to do something different within their practice that they currently do the fact remains is that a child with early onset scoliosis young kid that's having you know substantial difficulties there really isn't a non-surgical treatment option available these are procedures that are happening and surgeons are struggling right now to find adequate technologies to do those procedures, perform those procedures. So I think technology wins in this space. There's a great hunger from the pediatric orthopedic community to have technologies that can benefit these kids. And a lot of times surgeons are forced to use kind of last resort types of products. So these procedures are happening. And so I think, you know, if we have better technology, which we believe we will, and then we can round that technology out with three different products, we think really the three products you would need to take care of this very tough set of indications gives us a real distinct competitive advantage. And we do think that the uptick can be really strong with these product lines. And again, I think as much as the uptick in the EOS revenue, it also places the company in, I believe, a fairly prestigious spot in the minds of our customers that say we're willing to take on the extremely difficult things. that the majority of ortho is just not taking on. I mean, these are pretty fairly rare conditions, but they're very complicated, and surgeons haven't historically had great partnerships to take care of these kids. So we think that kind of creates, again, another halo around the business, gives us an opportunity to help more kids, but also will probably drive the usage profile of the balance of our other products.
spk12: Thank you.
spk14: And I'm currently showing no further questions at this time. I'd like to hand the call back over to David Bailey for closing remarks.
spk07: Thank you. Well, I'd like to thank everybody for joining us today. We've got an exciting week here at ePosna. I think this will be the largest meeting of the pediatric orthopedic community in history. And so we're excited to get out there and meet with customers, show off what we've done, and it's just no better place to talk about you know, a fantastic quarter for us and all the momentum we have heading into the balance of 2024. So appreciate everybody being on the call. Great questions. And we'll look forward to reporting on how things go as we progress. Take care.
spk14: This concludes today's conference call. Thank you for your participation. You may now disconnect.
Disclaimer